145774-33-0

Usage

Uses

Used in Research Applications:
C8 DIHYDROCERAMIDE is used as a negative control for C8 Ceramide for [application reason] because it serves as a comparative reference in experiments to better understand the effects and functions of C8 Ceramide.
Used in Pharmaceutical Industry:
C8 DIHYDROCERAMIDE is used as a negative control for C8 Ceramide in the pharmaceutical industry to ensure the accuracy and reliability of drug development and testing processes.
Used in Cosmetics Industry:
C8 DIHYDROCERAMIDE is used as a negative control for C8 Ceramide in the cosmetics industry to evaluate the effectiveness of various skincare products and formulations containing C8 Ceramide.
Used in Biomedical Research:
C8 DIHYDROCERAMIDE is used as a negative control for C8 Ceramide in biomedical research to study the biological effects and potential therapeutic applications of C8 Ceramide in various diseases and conditions.

Upstream product

• 764-22-7 (2S,3R)-2-amino-1,3-octadecanediol 
• 111-64-8 n-octanoic acid chloride 

Relevant academic research and scientific papers

USE OF A 2-AMINO-ALKANE POLYOL AS AGENT FOR TREATING SKIN AGEING SIGNS

The invention concerns the use, as main active principle in a composition or for preparing a pharmaceutical composition, of an effective amount of at least a 2-amino-alkane polyol, or one of its derivatives for treating skin ageing signs.

The synthesis and biological characterization of a ceramide library

A facile synthesis of a combinatorial ceramide library and their activities in the NF-κB pathway and in apoptosis induction/prevention were demonstrated. A novel NF-κB activating molecule was discovered among ceramide containing β-galactose, and the structural requirements of ceramides for apoptosis induction was elucidated. Copyright

2-amino-1,3-alkanediol compositions for inducing/stimulating hair growth and/or retarding hair loss

Topically applicable hair growth-/hair loss-affecting cosmetic/pharmaceutical compositions for treating mammalian subjects with hair or scalp disorders, comprise an effective amount of at least one 2-amino-1,3-alkanediol compound having the structural formula (I): formulated into a physiologically topically acceptable carrier medium therefor.